Analytical Data
-
Gene name
IFNA7
- Application
-
Alternative Names
IFNA7;Interferon alpha-7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01567
-
Expression Region
24-189aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSHMCDLPQ THSLRNRRAL ILLAQMGRIS PFSCLKDRHE FRFPEEEFDG HQFQKTQAIS VLHEMIQQTF NLFSTEDSSA AWEQSLLEKF STELYQQLND LEACVIQEVG VEETPLMNED FILAVRKYFQ RITLYLMEKK YSPCAWEVVR AEIMRSFSFS TNLKKGLRRK D
-
Molecular Weight
22 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNA7, a member of the interferon alpha family, plays a crucial role in the immune response against viral infections and has garnered attention for its potential therapeutic applications. The research background of IFNA7 recombinant protein focuses on its ability to modulate immune responses, offering insights into its efficacy as an antiviral agent. With the rise of viral diseases and the need for effective treatments, the exploration of IFNA7 has intensified, particularly in relation to its mechanism of action, signaling pathways, and interactions with various cell types. Studies have shown that IFNA7 can enhance the activity of natural killer cells and promote the formation of antiviral proteins, thereby contributing to the host's defense system. Additionally, recombinant forms of IFNA7 are being investigated for their potential in clinical settings, such as chronic viral infections and certain malignancies. The advancement of biotechnological methods has enabled the production of IFNA7 in sufficient quantities for research and potential pharmaceutical use, paving the way for innovative therapies targeting viral infections and immune-related disorders. This area of research not only aims to elucidate the biological significance of IFNA7 but also seeks to harness its immunomodulatory properties for developing novel therapeutics, transforming our approach to combatting viral diseases in an increasingly complex medical landscape.
